Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:03 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Trial of AZD5363 Plus Paclitaxel /AZD2014 Plus Paclitaxel in Biomarker Negative (PIK3CA/MEK/RAS/TP53/MET) Gastric Adenocarcinoma Patients as Second-line Chemotherapy
NCT02449655 · Samsung Medical Center · PHASE2 · terminated · last registry update 2019-05-20 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “lack of efficacy” | – | Registry record, Samsung Medical Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against AKT2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-03-12Phase 3 first posted: AstraZeneca, Fulvestrant + Capivasertib (NCT04305496)
- 2020-02-24Results posted on the registry: National Cancer Institute (NCI), Trametinib + Uprosertib (NCT01979523)
- 2019-12-05Results posted on the registry: National Cancer Institute (NCI), Akt Inhibitor MK2206 + Bicalutamide (NCT01251861)
- 2019-11-26Phase 3 first posted: Hoffmann-La Roche, Atezolizumab + Ipatasertib (NCT04177108)
- 2019-11-12Results posted on the registry: Merck Sharp & Dohme LLC, MK-2206 + docetaxel (NCT00848718)
- 2019-10-10Also stopped (terminated): National Cancer Institute (NCI), Akt Inhibitor MK2206 + Everolimus (NCT01239342)
- 2019-07-09Results posted on the registry: Novartis Pharmaceuticals, GSK2110183 (afuresertib) (NCT01531894)
- 2019-06-25Phase 3 first posted: AstraZeneca, Capivasertib + Paclitaxel (NCT03997123)
- 2019-04-04Phase 3 first posted: Karolinska Institutet, Enzalutamide Oral Capsule + Abiraterone Oral Tablet (NCT03903835)
- 2019-04-01Results posted on the registry: Merck Sharp & Dohme LLC, MK-2206 (NCT00670488)
- 2018-10-31Results posted on the registry: Merck Sharp & Dohme LLC, MK-2206 + Trastuzumab (NCT00963547)
- 2018-09-20Results posted on the registry: Genentech, Inc., Ipatasertib + Paclitaxel (NCT02301988)
- 2018-08-16Also stopped (terminated): Merck Sharp & Dohme LLC, dalotuzumab + MK-0752 (NCT01243762)
- 2018-08-07Results posted on the registry: Merck Sharp & Dohme LLC, MK-2206 + AZD6244 (NCT01021748)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision